A phase II study of aroplatin [L-NDDP; Aronex Pharmaceuticals] in subjects with recurrent, unresectable and metastatic colorectal cancer refractory to 5-fluorouracil (F-FU)/leucovorin or capecitabine, and irinotecan

Trial Profile

A phase II study of aroplatin [L-NDDP; Aronex Pharmaceuticals] in subjects with recurrent, unresectable and metastatic colorectal cancer refractory to 5-fluorouracil (F-FU)/leucovorin or capecitabine, and irinotecan

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2005

At a glance

  • Drugs L NDDP (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top